港股異動 | 愛康醫療創新高後回落 現跌逾3% 遭執董張朝陽三日減持700萬股
格隆匯4月15日丨愛康醫療(1789.HK)今年迄今已累漲逾1.3倍,今日盤中高見21.65港元創新高,後股價回落。現報20.5港元,跌3.76%,暫成交1.2億港元,最新總市值226億港元。根據聯交所最新權益披露資料顯示,愛康醫療於4月7日、8日及9日遭執行董事兼高級副總裁張朝陽在場內以每股均價18.94港元、18.95港元及18.91港元分別減持230萬股、230萬股及240萬股;三日合計減持700萬股,涉資約1.33億港元。減持後,張朝陽最新持股數目為5881.85萬股,持股比例由5.95%降至5.32%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.